Home >
Real Endpoints Marketplace for addressing high cost orphan medical benefit drugs is included in MIT’s white paper on emerging market solutions to address coverage and reimbursement challenges faced by durable cell and gene therapies.
News
<>
June 17, 2021
Real Endpoints Marketplace for addressing high cost orphan medical benefit drugs is included in MIT’s white paper on emerging market solutions to address coverage and reimbursement challenges faced by durable cell and gene therapies.
